AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00233324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Supplemental oxygen with target saturation of 91 to 95%
Description: Supplemental oxygen in the range of 91% to 95% until the infant is no longer requiring ventilatory support or oxygen.
Study NCT01749397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: Given IV
Study NCT00624442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CK-1827452
Description: IV infusion for 1 hour at 1.0 mg/kg/h followed by 1 hour at 0.5 mg/kg/h
Study NCT00624442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CK-1827452
Description: IV infusion for 1 hour at 0.25 mg/kg/h followed by 1 hour at 0.125 mg/kg/h followed by 22 hours at 0.025 mg/kg/h
Study NCT00835965 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Dexamethasone
Study NCT00624442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CK-1827452
Description: IV infusion for 1 hour at 0.5 mg/kg/h followed by 1 hour at 0.25 mg/kg/h followed by 22 hours at 0.05 mg/kg/h
Study NCT00624442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CK-1827452
Description: IV infusion for 1 hour at 1.0 mg/kg/h followed by 1 hour at 0.5 mg/kg/h followed by 22 hours at 0.1 mg/kg/h
Study NCT04287335 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Multitarget stool FIT-DNA test - ColoClear
Description: Multitarget stool FIT-DNA test
Study NCT04287335 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: FIT
Description: fecal immunochemical test
Study NCT04287335 — intervention group
Intervention type: PROCEDURE
Intervention: Colonoscopy
Description: diagnostic colonoscopy
Study NCT00624442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: IV infusion for 2 hours
Study NCT00624442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: IV infusion for 24 hours
Study NCT03502980 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bard PowerPICC
Description: PICC Insertion
Study NCT03502980 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bard PowerMidline catheter
Description: Midline Insertion
Study NCT01696851 — intervention group
Intervention type: OTHER
Intervention: tests and questionnaires
Description: lung test, depression and self-efficacy questionnaires and Functional testing.
Study NCT01366430 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gufoni
Description: For Gufoni maneuver, the patient was quickly brought down on the healthy side from the sitting position, and the head was then turned about 45 degree down, so that the nose was on the bed. After 2 minutes in this position, the patient was returned to the upright position.
Study NCT01366430 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sham
Description: The sham maneuver the opposite of the first step for barbecue rotation; lying down from sitting position for 30 seconds, and head turn 90degree to the affected side for 1 minute, and then sit up.
Study NCT01366430 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Barbecue
Description: For barbecue rotation, the head was rotated rapidly 90degree while supine in the direction of the healthy ear, which was immediately followed by a truncal rotation of 90degree in the same direction to lie on the intact side. After 30-60 seconds when the induced nystagmus was dissipated, the patients were subjected to a further 90degree rotation of the head and trunk en block in the same direction to attain the nose-down position. After a further 30-60 seconds, the head was again turned in the same direction so that the affected ear was downward. Finally, after another 30-60s, the patient was brought to sitting position. Only one maneuver was performed per session.
Study NCT05377892 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary protein
Description: High protein followed by reduced protein diet
Study NCT03805711 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HLT® Transcatheter System
Description: Transcatheter aortic valve replacement using The HLT® Transcatheter System (HLT System) in patients with symptomatic heart disease due to severe aortic stenosis who are judged by the Heart Team to be at Intermediate or High Risk for aortic valve replacement surgery (Heart Team agrees that the risk of 30-day mortality is ≥ 3%).
Study NCT03450174 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In control group, participants will receive only a placebo product
Study NCT03450174 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Formative messgaes
Description: In this group, participants will only receive daily formative messages
Study NCT03450174 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fortified product
Description: In this group, participants will receive fortified product on alternate day up till 8 months
Study NCT03450174 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Fortified product plus
Description: In this group participants will receive fortified product on alternate day and formative messages up till 8 months
Study NCT00626392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: niacin extended-release (NER)
Description: Tablets administered once daily; titrated to 2000 mg maximum dose during coadministration period
Study NCT00719420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin, Metronidazole, Amoxicillin (+Omeprazole)
Description: Clarithromycin 500 mg bid, metronidazole 500 mg tid, and amoxicillin 500mg tid with or without omeprazole 20 mg bid for 14 days
Study NCT00719420 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin, Amoxicillin, Omeprazole
Description: Clarithromycin 500 mg bid, amoxicillin 1 g bid, and omeprazole 20 mg bid for 10 days
Study NCT02010775 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: botulinum toxin Type A
Description: Botulinum toxin Type A (BOTOX®) administered intramuscularly to the bilateral masseter muscles on Day 1 and retreatment at Day 180 if applicable.
Study NCT03832023 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Screening and initiating preventive therapy in communities
Description: Symptom-based screening of tuberculosis household child contacts by community health workers; initiation of preventive therapy (3 months of a fixed-dose combination of rifampicin-isoniazid or 6 months isoniazid for HIV+ children on protease inhibitors) in the household by a nurse; follow-up of children under preventive therapy by a community health worker for eligible children at community level, and referral of presumptive tuberculosis cases (children and adults) to the facility.
Study NCT00626392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspirin (ASA)
Description: 325 mg tablets administered once daily
Study NCT00626392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspirin placebo (ASA Pbo)
Description: Tablets administered once daily
Study NCT00772421 — intervention group
Intervention type: DEVICE
Intervention: There was no intervention.
Description: There was no intervention. This study was designed as an in-clinic testing protocol to identify recruitment rhythms.
Study NCT02192320 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: 20 mg (every evening orally) for 5 weeks
Study NCT02192320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin and Dexamethasone
Description: Atorvastatin: 20 mg (every evening orally) for 5 weeks;~Dexamethasone:0.75mg Tid (1st-2nd week), 0.75mg Bid (3th week), 0.75mg Qd (4th week), 0.375mg Qd (5th week)
Study NCT00624442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CK-1827452
Description: IV infusion for 1 hour at 1.0 mg/kg/h followed 1 hour at 0.5 mg/kg/h followed by 70 hours at 0.1 mg/kg/h
Study NCT00624442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: IV infusion for 72 hours
Study NCT00624442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CK-1827452
Description: IV infusion for 1 hour at 0.75 mg/kg/h followed 1 hour at 0.5 mg/kg/h followed by 70 hours at 0.1 mg/kg/h
Study NCT01830894 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: 3 MRI on different times during the study for each arm.
Study NCT03240835 — intervention group
Intervention type: DRUG
Intervention: cisplatin and docetaxel
Description: NACt：cisplatin 75 mg/m2 intravenous infusion in day1，docetaxel 75 mg/m2 intravenous infusion in day1，both drugs are given every 3 weeks, two cycles.~CCRT: cisplatin (100mg/m2 on day 1) every three weeks for two cycles.
Study NCT03240835 — intervention group
Intervention type: RADIATION
Intervention: IMRT
Description: intensity modulation radiation therapy
Study NCT03286335 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Radiation
Description: Radiation treatment
Study NCT04170751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 16 mcg / cc of norepinephrine(group N)
Description: In group N, 16 mcg / cc of norepinephrine was infused through the central catheter. Drug titration should be 0.05 mcg / min / kg for norepinephrine and 2 units / hr for vasopressin, until target blood pressure is reached. Drug infusion rate should not exceed 0.3mcg / min / kg for norepinephrine and 10unit / hr for vasopressin for patient's safety.
Study NCT04170751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.4 unit / cc of vasopressin(group V)
Description: In group V, 0.4 unit / cc of vasopressin was infused through the central catheter and the respective doses recorded. Drug titration should be 0.05 mcg / min / kg for norepinephrine and 2 units / hr for vasopressin, until target blood pressure is reached. Drug infusion rate should not exceed 0.3mcg / min / kg for norepinephrine and 10unit / hr for vasopressin for patient's safety.
Study NCT04734405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prof-001
Description: Prof-001 cream
Study NCT04734405 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluconazole 150 mg
Description: Fluconazole capsule
Study NCT04734405 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo cream
Description: ointment base to mimic Prof-001
Study NCT04734405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo capsule
Description: encapsulated lactose powder to mimic 150 mg fluconazole capsule
Study NCT00648492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Hydrochloride ER Tablets 500 mg
Description: 500mg, single dose fed
Study NCT04061031 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent-Child Interaction Therapy (PCIT)
Description: A trained clinician teaches the caregiver to deliver a number of behavior modification techniques for use with the child and coaches the caregiver in the delivery of those techniques.
Study NCT04061031 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Child-Centered Therapy with Parent Education
Description: A trained clinician delivers non-directive, child-centered treatment techniques with the child while providing education to the parent based on current recommendations from the Department of Health and Human Services' Child Welfare Information Gateway.
Study NCT00788138 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: 250,000 IU of vitamin D3
Study NCT00648492 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucophage® XR 500 mg
Description: 500mg, single dose fed
Study NCT00788138 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo
Study NCT03534843 — intervention group
Intervention type: PROCEDURE
Intervention: Liver resection
Description: Liver resection was comprised of single or multiple liver resections aiming to excise all macroscopic tumors.
Study NCT03534843 — intervention group
Intervention type: OTHER
Intervention: Transcatheter arterial embolization
Description: Transcatheter arterial embolization or transcatheter arterial chemoembolization can localize the bleeding point and provide interventional embolization.
Study NCT00462124 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Absorbable perirectal spacer
Description: biodegradable balloon implant to increase the distance between prostate and anterior rectal wall
Study NCT03906578 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vivomixx®
Description: Microbiotic food supplement with L. paracasei, L. plantarum, L. acidophilus, L. delbrueckii, B. longum, B. infantis, B. breve, S. thermophilus
Study NCT03906578 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo with similar appearance to probiotic
Study NCT05937997 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: high intensity physiotherapy
Description: high intensity exercises for 3 weeks inpatient rehabilitation
Study NCT00624442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CK-1827452
Description: IV infusion for 1 hour at 0.25 mg/kg/h followed by 23 hours at 0.025 mg/kg/h
Study NCT05937997 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: moderate intensity physiotherapy
Description: moderate intensity exercises for 3 weeks inpatient rehabilitation
Study NCT03742271 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: senofilcon A
Description: TEST Lens
Study NCT05937997 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: low intensity physiotherapy
Description: low intensity exercises for 3 weeks inpatient rehabilitation
Study NCT02676583 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tonsillectomy
Description: Closure or not closure of tonsil fossa
Study NCT04472650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitravatinib
Description: Administered orally as a free base capsule
Study NCT04472650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitravatinib
Description: Administered orally as a malate salt capsule
Study NCT02777450 — intervention group
Intervention type: PROCEDURE
Intervention: lumbar facet block
Description: injection of Levobupivacaine 0,25% and corticosteroids
Study NCT00624442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CK-1827452
Description: IV infusion for 1 hour at 0.5 mg/kg/h followed by 23 hours at 0.05 mg/kg/h
Study NCT00418600 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Hectorol® (doxercalciferol capsules)
Description: Hectorol capsules at 1.0 times current injection dose
Study NCT00418600 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: doxercalciferol capsules, Hectorol®
Description: Hectorol capsules at 1.5 times current injection dose
Study NCT00418600 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: doxercalciferol capsules, Hectorol® capsules
Description: Hectorol capsules at 2.0 times current injection dose
Study NCT01435473 — intervention group
Intervention type: PROCEDURE
Intervention: Cardiac Surgery
Study NCT02552173 — intervention group
Intervention type: RADIATION
Intervention: The Relationship Between Operative and Radiologic Stem Version
Description: intraopertive surgeon's estimation and postoperative CT scan
Study NCT00626782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Ranibizumab 0.5mg (0.05mL)one injection in sub-tenon's at the conclusion of glaucoma surgery
Study NCT00626782 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitomycin (MMC)
Description: Mitomycin (MMC) C 0.4 mg/ml applied with soaked pledget inserted in the sub-tenon's space during glaucoma surgery.
Study NCT02010775 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline (placebo) administered intramuscularly to the bilateral masseter muscles.
Study NCT04234178 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epidural
Description: 2 µg/ml fentanyl + %0,125 bupivacaine (20 ml) to epidural
Study NCT04234178 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal+Epidural
Description: 10 µg fentanyl + 2 mg bupivacaine to intrathecal 7.4 ml saline volume to epidural
Study NCT00592943 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: armodafinil
Description: tablet, taken by mouth, once each study day
Study NCT01500694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended-release Guanfacine HCl (Intuniv, SPD503)
Description: Subjects will be dosed orally once-daily in the AM at 1, 2, 3, 4, 5, 6, or 7 mg according to subjects weight and age
Study NCT03980002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FCR and Ibrutinib
Description: Induction treatment:~Patients \<65 y and without significant comorbidities are given FCR 1or 2 courses (If patients' white blood cell count \<10×10\^9/L after first course, the second course can be saved). Then, patients takes ibrutinib orally for 3 months alternating with FCR in 2 cylcles.~1. FCR： F（Fludarabine）：25mg/m2·d，d1-3； C（Cyclophosphamide）：CTX 250mg /m2·d，d1-3； R（Rituximab）：375mg/m2 d0（first course），500mg/m2 d0（subsequent courses）；~2. Ibrutinib:420mg/d
Study NCT03363568 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adaptive Inhibitory Control Training
Description: Playing computerized stop-signal reaction time tasks that had been modified to increase in difficulty as performance increased.
Study NCT03363568 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-adaptive Inhibitory Control Training
Description: Playing computerized stop-signal reactions time tasks that do not change in difficulty level (non-adaptive).
Study NCT04237610 — intervention group
Intervention type: BEHAVIORAL
Intervention: behavioral assessment
Description: Probabilistic learning task
Study NCT01567475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus and rituximab
Description: One injection of Rituximab 375 mg/m2 per week during 28 days followed by one Rituximab infusion every other cycle at 375 mg/m2 associated with everolimus at 5mg or 10 mg every day or 5 mg every other day.
Study NCT05179538 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cued picture-naming therapy
Description: The proposed study will administer Cued Picture-Naming Treatment (CPNT) four days per week for four weeks (i.e. 16 sessions). During therapy, participants will attempt to name eight consecutive presentations of the same black and white picture, for each of the 20 pictures, with cueing from the administrator. Trials will include (1) independent naming, (2) orthographic cueing (i.e. the written word beneath the picture.), (3) repeating, (4) naming after a short delay (i.e. approximately three seconds), (5)semantic cueing (i.e. three cues providing semantic information about the target will be spoken to the participant by the clinician), (6) phonological cueing (i.e. the first sound and letter will be spoken by the clinician), (7) repeating, and (8) naming after a short delay. The administrator will provide the correct response for each incorrect participant response and will ask the participant to repeat it.
Study NCT02418663 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Fluid challenge (250 ml Lactated Ringer's solution)
Description: When VE is prescribed to a patient, a fluid challenge of 250mL Lactated Ringer's solution will first be administered. The ccNexfin system will be used to predict FR (SV increases by at least 15% in response to a fluid challenge). The remaining amount of fluid ordered by the treating team will then be administered, and SV will again be measured.~Additionally, a daily fluid challenge with 250mL of Lactated Ringer's will also be administered, with FR recorded as above
Study NCT04032249 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Group (CG)
Description: The control group is subjected to follow a hypocaloric diet and receives information about the benefits of having healthy habits in relation to decision making and food
Study NCT04032249 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Group (IG)
Description: The control group is subjected to follow a hypocaloric diet and receives information about the benefits of having healthy habits in relation to decision making and food, but also, they will have monitored the self-control of the weight in order to compare the impact of self-weighing versus not doing it
Study NCT04447950 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Type 2/posterior Quadratus Lumborum block
Description: Injection of local anaesthetic into posterior boundry of Quadratus Lumborum muscle.
Study NCT04447950 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo block with Saline
Description: Injection of saline into posterior boundary of Quadratus Lumborum muscle.
Study NCT03980002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR and Ibrutinib
Description: Induction treatment:~Patients ≥65y and ≤75 y or \<65 y but with comorbidities, are given BR 1or 2 courses (If patients' white blood cell count drop to below10×10\^9/Lafter first course, the second course can be saved). Then, patients takes ibrutinib orally for 3 months alternating with BR in 2 cylcles. 1.BR： B（Bendamustine）：90mg/m2·d，d1-2； R（Rituximab）：375mg/m2 d0（first course），500mg/m2 d0（subsequent courses）； 2. Ibrutinib: 420mg/d
Study NCT03980002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib and Thalidomide
Description: Maintenance treatment:~After induction treatment, recommend ( but not mandatory) Ibrutinib or thalidomide monotherapy(according to patients preferrance) for MRD-positive patients.For MRD-negative patients, recommend ( but not mandatory) no maintenance therapy.